The heightened susceptibility to mutagenesis and disrupted transcriptional regulation observed in ATRX-deficient gliomas, sarcomas, and other neuroendocrine tumours suggests that similar mechanisms could contribute to the aggressive and proliferative behaviours seen in rare PitNET subtypes. Here, ATRX is linked to central nervous system cancer.